tirzepatide and heart health Beneficial for Failure With Preserved EF, Obesity Does Tirzepatide Lower Blood Pressure?

doi: 10.3389/fendo.2022.1012412 Received 05 August 2022 Accepted 12 September 2022 Published 04 October 2022 Volume 13 - 2022 Edited by Jehad Ahmed Abubaker, Dasman Diabetes Institute, Kuwait Reviewed by Wataru Nishimura, International University of Health and Welfare School of Medicine, Japan

In contrast, human clinical trials of semaglutide (injectable) and tirzepatide (injectable) show substantially larger mean weight reductions over similar or longer follow-up periods

In conclusion, semaglutide significantly reduced NT-proBNP levels in patients with obesity-related HFpEF in the STEP-HFpEF program

Studies in anaesthetised pigs has shown that GLP-1 clearance involves multiple organs including hepatic, peripheral and renal extraction, whereas exendin-4 is subject solely to glomerular filtration, which also appears to be up to two-fold slower than native GLP-1 (134)

A managed switch usually includes: Most patients can switch without major disruption when there is a clear plan